Comment on "Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study."

Haematologica. 2021 Apr 1;106(4):1226-1227. doi: 10.3324/haematol.2020.278203.NO ABSTRACTPMID:33792226 | PMC:PMC8018111 | DOI:10.3324/haematol.2020.278203

Source: Haematologica - April 1, 2021 Category: Hematology Authors: Marco Picardi Claudia Giordano Source Type: research